3-Acetyl-4,5,6,7-tetrahydro-indazol | 4492-04-0

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 3-Acetyl-4,5,6,7-tetrahydro-indazol
• 英文别名: 1-(4,5,6,7-tetrahydro-1H-indazol-3-yl)-ethanone；1-(4,5,6,7-tetrahydro-1H-indazol-3-yl)ethan-1-one；1-(4,5,6,7-tetrahydro-1H-indazol-3-yl)ethanone
• CAS: 4492-04-0
• 化学式: C₉H₁₂N₂O
• 分子量: 164.207
• InChiKey: VVTQODCJOVJAFY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  45.8
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• Phenyl pyrrolidine ether tachykinin receptor antagonists
  申请人：DeVita J. Robert

  公开号：US20070043015A1

  公开（公告）日：2007-02-22

  The present invention is directed to certain phenyl pyrrolidine ether compounds which are useful as neurokinin-1 (NK-1) receptor antagonists, and inhibitors of tachykinin and in particular substance P. The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in the treatment of certain disorders, including emesis, depression, and anxiety.

  本发明涉及某些苯基吡咯烷醚化合物，其作为神经激肽-1（NK-1）受体拮抗剂和快速激肽，特别是物质P的抑制剂具有用途。本发明还涉及包含这些化合物作为活性成分的制药配方以及这些化合物及其配方在治疗某些疾病，包括呕吐、抑郁和焦虑方面的应用。
• Compounds
  申请人：Alcaraz Lilian

  公开号：US20090298807A1

  公开（公告）日：2009-12-03

  The present invention relates to spirocyclic amide derivatives of the formula I, pharmaceutically acceptable salts thereof, a process for their preparation, pharmaceutical compositions containing them, and their use in therapy.

  本发明涉及公式 I 的螺环酰胺衍生物，其药学上可接受的盐，其制备方法，含有它们的制药组合物以及它们在治疗中的应用。
• TRICYCLIC INDAZOLE COMPOUND, METHOD OF PREPARATION AND PHARMACEUTICAL COMPOSITION CONTAINING IT
  申请人：Alisi Maria Alessandra

  公开号：US20130023524A1

  公开（公告）日：2013-01-24

  Tricyclic indazole compound and its pharmaceutically acceptable salts of acid addition, use thereof, method and intermediates for preparing them, and a pharmaceutical composition containing them. The tricyclic indazole compound has the following general Formula (I): in which R 1 , R 2 , L 1 , L 2 , X 1 , X 2 , X 3 , X 4 , X 5 , Y, W, m, and n have the meanings stated in the description.

  三环吲唑化合物及其药学上可接受的酸盐，其使用方法，制备方法及中间体，以及包含它们的药物组合物。三环吲唑化合物具有以下一般式（I）：其中R1，R2，L1，L2，X1，X2，X3，X4，X5，Y，W，m和n具有所述描述中的含义。
• SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF
  申请人：Millennium Pharmaceuticals, Inc.

  公开号：US20140329836A1

  公开（公告）日：2014-11-06

  This invention provides compounds of formula (I): wherein R 1 , R 2 , G, n, p and q have values as described in the specification, useful as inhibitors of HDAC6. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of proliferative, inflammatory, infectious, neurological or cardiovascular diseases or disorders.

  本发明提供了式(I)的化合物：其中R1、R2、G、n、p和q的值如规范所述，可用作HDAC6的抑制剂。本发明还提供了包含本发明化合物的制药组合物和使用该组合物治疗增生性、炎症性、感染性、神经系统或心血管疾病或障碍的方法。
• US7468437B2
  申请人：——

  公开号：US7468437B2

  公开（公告）日：2008-12-23